



LifePulse ® Corporation Secures Major Distribution Agreement with Patterson Veterinary

FOR IMMEDIATE RELEASE

November 20, 2025

LifePulse ® Corporation Secures Major Distribution Agreement with Patterson Veterinary

TAMPA, Fla. — LifePulse ® Corporation, a global leader in Pulsed Electrical Field (PEF) technology, reached a wide-ranging distribution agreement Sept. 25, 2025, with global veterinary supply company Patterson Veterinary, to distribute LifePulse's patented VetPulse ® 2000 device.

The VetPulse ® 2000 presents a revolutionary, minimally-invasive treatment option for cancerous tumors in animals including horses, dogs, cats and more with patented technology that changes PEF for the first time in nearly 60 years.

Revolutionizing Cancer Treatment in Animals

Unlike older modalities, technology developed by LifePulse ® Corporation reduces twitching and pain, creating safer, faster procedures for both small and large animals, including horses and cattle.

The VetPulse ® 2000 uses a process called electroporation. Electroporation— electronic pulse technology which creates temporary pores in cell membranes through which therapies can be administered— has been proven to be effective in treating an array of medical conditions.

The VetPulse ® 2000, LifePulse's patented pulsed electrical medical device, uses short bursts of electrical energy to target tissue, enabling delivery of therapy to cells with precision. The VetPulse ® 2000 does this while minimizing impact to surrounding areas with much lower voltage than legacy methods. The device is additionally designed to enable clinicians to measure delivery of the therapeutic being delivered in real time, preventing over and under treatment.

Veterinary practices in the U.S., the UK, and Canada will now have access to the VetPulse ® 2000 technology through Patterson Veterinary.

“We are thrilled to be offering LifePulse's patented device to our portfolio, changing the way we provide care,” shared Jonathan Butz, Patterson Veterinary Director of Equipment & Technology Service. “One of Patterson's values is always advancing, and I can't think of a better way to live that out than to offer a technology advancing the life of animals.”

Practitioners can witness Patterson's launch of the device at two upcoming conferences: Dec. 6-10, 2025 at The American Association of Equine Practitioners conference in Denver, Colo., and Jan. 17-21, 2026 at The World Classic Veterinary Conference in Orlando, Fla.

“This is a turning point—not only for veterinary care, but soon for human medicine as well,” said Gary Strange, LifePulse Chairman and Founder. “Partnering with Patterson ensures immediate and widespread access to life-extending technology that can change the way we treat cancer in animals.”

LifePulse ® Corporation is dedicated to developing medical solutions that extend both animal and human lives through a growing portfolio of patents, devices, and pharmaceuticals.

About Patterson Veterinary

Patterson Veterinary, a subsidiary of Patterson Companies Inc , connects animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network, and supply chain are equaled only by our dedicated, knowledgeable people who deliver unrivaled expertise and unmatched customer service and support. Learn more: www.pattersonveterinary.com.

For media queries, please contact: alexandra.hays@lifepulse.co.

Find LifePulse ® Corporation on the [Web](#) and [LinkedIn](#)

Caption:

The VetPulse 2000 device, shown above, developed by LifePulse ® Corporation as an innovative minimally-invasive treatment option for cancerous tumors in animals, will soon be distributed by Patterson Veterinary in the U.S., United Kingdom, and Canada.